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Abstract
The antiepileptic, levetiracetam (LEV), has been investigated for the treatment of alcohol abuse.
However, little is known about how LEV alters the behavioral effects of alcohol in laboratory
animals. The acute effects of LEV on alcohol drinking by male C57BL/6J mice were investigated
using two different drinking procedures, limited access (drinking-in-the-dark, or DID) and
intermittent access (IA) drinking. In the first experiment (DID), mice had access to a single bottle
containing alcohol or sucrose for four hours every-other day. In the second experiment (IA), mice
had intermittent access to two bottles, one containing alcohol or sucrose and one containing water,
for 24 h on Mon/Wed/Fri. In both experiments, mice were administered LEV (0.3 – 100 mg/kg
i.p.) or vehicle 30 min before access to the drinking solutions. In the DID mice, LEV increased
alcohol intake from 4.3 to 5.4 g/kg, while in the IA mice LEV decreased alcohol intake from 4.8
to 3.0 g/kg in the first 4 h of access and decreased 24 h alcohol intake from 20 g/kg to
approximately 15 g/kg. These effects appear specific to alcohol, as LEV did not affect sucrose
intake in either experiment. LEV appears to differentially affect drinking in animal models of
moderate and heavier alcohol consumption.
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Introduction
Pharmacological treatments that either reduce the positive, rewarding effects of alcohol or
alleviate the consequences of withdrawal offer promise for reducing excessive alcohol
drinking (Heilig et al., 2010). However, only three medications, disulfiram, naltrexone, and
acamprosate have demonstrated efficacy and are approved by the U.S. Food and Drug
Administration for use in alcohol abuse disorders. No single pharmacological intervention
has proven effective in all individuals and this is not surprising given the biological and
behavioral variation among problem drinkers. As the need for personalized
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pharmacotherapy becomes more apparent, it is important to investigate both novel and
existing compounds across a range of conditions to understand in whom and how they may
be effective. While significant emphasis has been placed on genetic differences among
individuals, behavioral differences, such as individual pattern and history of alcohol use,
may also significantly impact treatment outcomes (Anton et al., 2004).
Anticonvulsants have been proven to be useful in the treatment of many psychiatric
disorders, and have been proposed to be useful for drug and alcohol addiction (Gass and
Olive, 2008). Levetiracetam (LEV) is an antiepileptic drug that alters glutamate and possibly
GABA neurotransmission (Meehan et al., 2011; Meehan et al., 2012; Robinson et al., 2013)
by interfering with the activity of synaptic vesicle protein 2A (SV2A), which has been
identified as the sole binding site for LEV in the brain (Lynch et al., 2004). In addition to its
efficacy in the treatment of epilepsy, LEV has been proposed for use in the treatment of
several neuropsychiatric disorders (e.g. post-traumatic stress disorder, chronic pain, social
anxiety), including alcohol abuse. Unlike topiramate, another antiepileptic drug under
consideration for maintenance of sobriety in alcoholics (Johnson et al., 2008; Shinn and
Greenfield, 2010), LEV is not associated with significant cognitive slowing as determined
by objective testing (Gomer et al., 2007) or subjective patient experience (Arif et al., 2009).
While several initial reports indicated that LEV may be useful to treat alcohol withdrawal in
detoxifying patients (Krebs et al., 2006; Mariani and Levin, 2008; Sarid-Segal et al., 2008;
Muller et al., 2010; Richter et al., 2010; Muller et al., 2011), subsequent studies have not yet
demonstrated that LEV reduces alcohol intake by self-identified heavy social drinkers or
individuals seeking treatment (Fertig et al., 2012; Mitchell et al., 2012; Richter et al., 2012).
There are few preclinical studies on the effects of LEV in animal models of drug and alcohol
abuse. Repeated LEV administration has been shown to reduce alcohol intake in female
alcohol-preferring rats (Zalewska-Kaszubska et al., 2011) and acute LEV administration has
been shown to alleviate the anxiety-like behaviors produced by benzodiazepine withdrawal
in mice (Lamberty et al., 2002). Acute LEV has been also shown to reduce the effects of
acute alcohol on both locomotor activation and the potentiation of intracranial self-
stimulation (ICSS), and independently reduces both the induction and expression of
locomotor sensitization to repeated alcohol exposure in male C57BL/6J mice (Robinson et
al., 2013). Most preclinical studies of LEV have focused on its anti-seizure efficacy. LEV
does not elevate seizure thresholds after acute electroshock or acute administration of
pentylenetetrazol (PTZ) but does raise thresholds following kindling or repeated PTZ dosing
(Klitgaard, 2001). It is possible that this characteristic of LEV action may also bear on
preclinical models of alcohol craving, in which neurobiological mechanisms similar to
seizure kindling may play a role (Becker, 1998; Breese et al., 2005; Modesto-Lowe et al.,
2005; Breese et al., 2011). There are several pre-clinical methods for alcohol intake that may
model specific patterns of human alcohol use and abuse (Becker, 2013). Of these,
intermittent rather than continuous access procedures are thought to produce more kindled
neural activity. Intermittent alcohol access procedures have also been shown to be sensitive
to pharmacological manipulations that continuous alcohol access procedures are not
(Nielsen et al., 2008; Hopf et al., 2010; Simms et al., 2013).
The current studies tested the hypothesis that acute LEV would specifically reduce alcohol
intake by C57BL/6J (C57) mice, using two previously published intermittent access
procedures. The first experiment examined the effects of different doses of LEV in a
modified “drinking-in-the-dark” (DID) procedure in which separate groups of mice had
access to either alcohol (20% v/v) or a sucrose solution (0.5%), of which a similar volume
was consumed, for 4 h every other day (Holstein et al., 2011). The second experiment
examined the effects of LEV in a 24-h intermittent access (IA) procedure in which separate
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groups of mice had access to alcohol (20% w/v) and water (Hwa et al., 2011) or an
similarly-consumed sucrose solution (0.5%) and water.
Methods
Subjects
Male C57BL/6J mice (n = 63; Jackson Labs, Bar Harbor, ME) arrived at 60 days of age
weighing at least 22 g, and were individually housed in clear, polycarbonate cages (28 × 17
× 14 cm) covered with stainless steel wire lids and lined with cob bedding. Fresh bedding
was provided once a week on a non-experimental day. Food (Purina rodent chow) and
drinking fluids were freely available, except when noted in the procedure section. The
vivarium was 21 ± 1 °C, 30–40% humidity, and on 12-hour dark/light cycle (lights off at
8:00 AM). All procedures were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of North Carolina and conducted according to the
NIH Guide for the Care and Use of Laboratory Animals (National Academic Press, eighth
edition, revised 2011).
Apparatus and Procedures
During experimental sessions, fluid was presented in 10 ml graduated cylinders (Corning,
Corning, NY), fitted with double ball-bearing stainless steel sipper tubes (Ancare, Bellmore,
NY), capped with silicone stoppers (LabPure, Poestenkill, NY) and secured to the cage lid.
Fluid was presented at 12:00 PM, 4 hours into the dark cycle. Intake levels were measured
to the nearest 0.1 ml and recorded hourly for the first four hours and after 24 hours in
experiment 2.
Experiment 1 (drinking-in-the-dark, DID) followed the procedure of Holstein et al. (2011).
Every other day, standard water bottles were removed from each cage and replaced with one
drinking tube containing either a 20% (v/v) alcohol (n = 13) or 0.5% (w/v) sucrose (n = 11)
solution. The 0.5% sucrose solution was chosen because preliminary studies determined that
it led to levels of intake that were comparable to those of 20% alcohol. On the first two
experimental days, the drinking tubes were in place for 2 h. On all other days, the drinking
tubes were in place for 4 h. When the drinking tubes were removed the water bottle was
returned. A stable history of alcohol intake was achieved after four weeks (i.e. 13 drinking
sessions) and the mice were habituated to injection. Saline was first given i.p. on three non-
experimental days and then given on three experimental days, 30 min before fluid access.
LEV injections were administered to each mouse at each dose (0.3, 3.0 10.0, 30.0 and 100
mg/kg) in a counter-balanced order 30 min before fluid access. Each LEV dose was
separated by four days, including an additional day of saline injection, to verify that there
were no carryover effects from the previous levetiracetam injection.
Experiment 2 (intermittent access, IA) followed the procedure of Hwa et al. (2011). Two
drinking tubes were presented to each mouse. On Monday, Wednesday, and Friday, one tube
contained water; the other contained either an alcohol (n = 11) or a sucrose (n = 12) solution.
The side of the alcohol/sucrose and water bottles alternated on each experimental day. On
Tuesday, Thursday, Saturday, and Sunday, both tubes contained tap water. The
concentrations of alcohol (3, 6, 10%, w/v) and sucrose (0.1, 0.17, 0.3%, w/v) were increased
over the first experimental week and remained at 20% (w/v) alcohol and 0.5% (w/v) sucrose
for the duration of the experiment. The purpose of increasing the alcohol concentrations was
to acclimate the mice to the taste of alcohol, while the purpose of increasing the sucrose
concentrations was to parallel the changes in alcohol concentrations. After five weeks of
intermittent alcohol drinking (i.e. 15 drinking days), habituation to saline injections and
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levetiracetam pretreatment before alcohol access was performed as described in experiment
1.
Drugs
Alcohol solutions were prepared by diluting 95% ethyl alcohol (Decon Labs, Inc., King of
Prussia, PA) with tap water. In keeping with Holstein et al. (2011), alcohol solutions were
prepared on a volume:volume basis for 4-h limited access (DID) experiments; likewise, in
keeping with Hwa et al. (2011), alcohol solutions were prepared on a weight:volume basis
for 24-h intermittent access (IA) experiments. Sucrose solutions were prepared using tap
water and D-sucrose (Sigma-Aldrich, St. Louis, MO). After habituation to saline injection,
levetiracetam (S-α-ethyl-2-oxo-pyrrolidine acetamide; Sigma- Aldrich, St. Louis, MO) was
dissolved in 0.9% saline and injected intraperitoneally through a 27 gauge needle.
Blood Alcohol Determination
To determine blood alcohol levels during the drinking session, tail vein blood samples
(approximately 40 µl) were taken after 2 h of alcohol intake on the last day of drinking, with
no injections administered prior to alcohol access. To determine whether LEV
administration directly affected the metabolism of alcohol, separate groups of mice were
injected with either saline (n=8) or levetiracetam (10.0 mg/kg, n=8) and 30 min later were
orally gavaged with 1.0 g/kg alcohol. Blood samples were collected 15, 45, and 75 minutes
after the alcohol injection. After collection, all blood samples were centrifuged and 5 µl of
plasma from each sample was used to determine alcohol concentration using an AM1
Alcohol Analyzer (Analox Instruments, Lunenburg, MA).
Data Analysis
The following measures were obtained: volume (ml) and amount (g/kg) of alcohol, sucrose,
and water consumed; total fluid consumed; and the preference ratio for alcohol or sucrose
([ml alcohol or sucrose/ ml total] x 100). Data from the multiple saline vehicle injections
were grouped into a single control value after a one-way repeated measures (saline
determination) analysis of variance (ANOVA) revealed no difference between different
determinations. The drinking data were then analyzed with one-way (LEV dose) repeated
measures ANOVA. Significant main-effects (p ≤ 0.05) were analyzed with post-hoc
Bonferroni tests for each LEV dose vs. the saline vehicle.
Results
Single Bottle, 4-H Limited Access (DID)
Alcohol and sucrose consumption was relatively stable across the first 11 drinking days with
4-h access (Figure 1). The average volumes (± SEM) of alcohol and sucrose solutions
consumed in the 4-h access sessions were 1.1 ± 0.03 ml and 1.9 ± 0.04 ml, respectively. The
average quantities (± SEM) of alcohol and sucrose consumed were 6.0 ± 0.15 g/kg and 0.34
± 0.01 g/kg, respectively. Saline injections given 30 min before the drinking session reduced
these volumes to 0.83 ± 0.01 ml and 1.25 ± 0.04 ml and quantities to 4.6 ± 0.01 g/kg and
0.21 ± 0.01 g/kg. LEV injection did not significantly affect cumulative sucrose intake at any
time during the 4-h access period (Figure 2). However, LEV treatment increased cumulative
alcohol intake (g/kg) during the second (F5,89 = 2.6; p < 0.05), third (F5,89 = 2.4; p < 0.05),
and fourth hours (F5,89 = 3.1; p < 0.01) of the 4-h access period (Figure 2). The 3.0 mg/kg
levetiracetam dose significantly increased alcohol intake during the second, third, and fourth
hours (all p < 0.04,) while the 10 and 30 mg/kg doses significantly increased alcohol intake
during the fourth hour (both p < 0.05) relative to saline injection.
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Two-Bottle Choice, 24-H Access (IA)
With 24-h access, alcohol and sucrose intakes were more variable across the first drinking
days than they were in experiment 1 (Figure 3). Prior to saline injection the average volumes
(± SEM) of alcohol and sucrose solutions consumed in the first 4 h of access were 1.0 ± 0.05
ml and 1.4 ± 0.04 ml, respectively. The average quantities (± SEM) of alcohol and sucrose
consumed were 6.8 ± 0.33 g/kg and 0.25 ± 0.02 g/kg, respectively. Saline injections given
30 min before the drinking session reduced these volumes to 0.83 ± 0.04 ml and 1.4 ± 0.11
ml and quantities to 5.6 ± 0.27 g/kg and 0.24 ± 0.02 g/kg.
24 h sucrose intake showed significant day-to-day variation (Figure 3, right panels), while
alcohol intake escalated across the first four weeks of access to the 20% solution (Figure 3D,
drinking days 4–15). Prior to saline injection, the average volumes (± SEM) of alcohol and
sucrose solutions consumed in the 24-h access sessions were 3.0 ± 0.15 ml and 3.7 ± 0.22
ml, respectively; and the average quantities (± SEM) of alcohol and sucrose consumed were
21.5 ± 0.99 g/kg and 0.66 ± 0.04 g/kg, respectively. After saline injections given 30 min
before the drinking session, these volumes were 2.99 ± 0.07 ml and 4.1 ± 0.02 ml and
quantities were 20.5 ± 0.54 g/kg and 0.70 ± 0.01 g/kg.
While there were significant main effects of LEV on sucrose intake in the first hour (F5,71 =
2.5; p < 0.05), second hour (F5,71 = 4.1; p < 0.005), third hour (F5,71 = 4.1; p < 0.005) and
fourth hour (F5,71 = 2.5; p = 0.05) (Figure 4), no single dose of LEV significantly increased
or decreased sucrose intake relative to saline injection. LEV did not significantly affect
sucrose intake or the sucrose preference ratio over the full 24-h drinking period (Figure 5).
LEV also had no significant effect on water intake in either the sucrose- or alcohol-drinking
mice at any time after injection (Table 1).
LEV reduced cumulative alcohol intake (g/kg) during the first (F5,65 = 5.3; p < 0.001),
second (F5,65 = 2.9; p < 0.02) and fourth (F5,65 = 4.8; p < 0.001) one-hour time periods
(Figure 4). The 10 mg/kg dose reduced intake in the first, second, and fourth hours (p <
0.05, 0.05, and 0.005, respectively). The 0.3 and 3.0 mg/kg doses significantly reduced
alcohol intake in the fourth hour (p < 0.02). During the third one-hour period, there was a
trend (F5,65 = 2.4; p = 0.052) for LEV to reduce alcohol intake. LEV treatment also reduced
the total cumulative 24-h alcohol intake (F5,65 = 4.5; p = 0.002) and the alcohol preference
ratio (F5,65 = 7.1; p < 0.001; Figure 5). Although 24-h intake was lower after all LEV doses,
only the 0.3, 10, and 100 (p < 0.001, 0.02, and 0.005, respectively) mg/kg doses resulted in
statistically significant reductions in alcohol intake. Alcohol preference was significantly
reduced by the 10 and 100 mg/kg doses (both p <0.001).
Levetiracetam Effects on Blood Alcohol Concentration
On the last day of drinking experiments, 2 h into the drinking sessions the average blood
alcohol concentration (BAC) was 74.7 ± 6.5 mg/dl. In separate mice, following 1.0 g/kg
alcohol p.g., there were no significant effects of 10 mg/kg levetiracetam i.p. on BAC at 15,
45, or 75 min post-gavage (Figure 6).
Discussion
The current experiments examined the effects of acute administration of the antiepileptic
drug levetiracetam (LEV) on alcohol and sucrose drinking in two different access
procedures. In the first experiment, using a modified “drinking-in-the-dark” (DID)
procedure, separate mice drank either alcohol or sucrose from single bottles that were
presented for four hours during the circadian peak of eating and drinking every-other day
(Holstein et al., 2011). This procedure achieved moderately high alcohol intakes
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(approximately 5 g/kg/4hr) that were stable across consecutive test days and were similar
between individuals. After the first hour of drinking, levetiracetam pretreatment increased
alcohol intake relative to saline pretreatment. Moderate LEV doses (3 – 30 mg/kg) had the
greatest effect, while the highest dose tested (100 mg/kg) did not increase alcohol intake. In
the second experiment, using an intermittent access (IA) procedure, separate mice drank
from two bottles, one containing alcohol or sucrose and the other containing water, placed
into their home cage for 24 h every Monday, Wednesday, and Friday (Hwa et al., 2011). In
contrast to the findings of the DID experiment, LEV decreased alcohol intake in the IA
procedure during the first four hours of access as well as over the entire 24-h access period.
In both DID and IA experiments, LEV did not consistently increase or decrease sucrose
intake, nor did LEV affect water intake measured concurrently during the IA procedure. The
opposing results from the two experimental procedures highlight the importance of
comparing drug effects on different models of alcohol access and intake.
Levetiracetam is approved by the U.S. Food and Drug Administration for the treatment of
epilepsy, and has both favorable pharmacokinetics and a modest side-effect profile (Sirsi
and Safdieh, 2007). Because of this, LEV has a wide therapeutic window, and high serum
levels can be safely obtained. The doses of LEV chosen for this study approximate the range
of weight-based doses used for seizure prevention in humans, typically 40–80 mg/kg/day.
Clinical studies of LEV in alcohol use disorders report using oral doses of 500–4500 mg
daily (Mariani and Levin, 2008; Sarid-Segal et al., 2008; Muller et al., 2010; Muller et al.,
2011), or 7–64 mg/kg/day in a 70 kg adult. LEV is virtually unaffected by hepatic
metabolism (Perucca and Johannessen, 2003; Lacerda et al., 2006), and in the current study
a 10mg/kg i.p. LEV dose did not affect BAC after experimenter-administered 1.0 g/kg
alcohol p.g., making it unlikely that changes in alcohol pharmacokinetics can account for
our behavioral findings. LEV crosses the blood-brain barrier freely, with peak serum
concentrations achieved within 30 min after i.p. administration and a serum half-life
between 1 and 3 h in rats and mice (Doheny et al., 1999; Benedetti et al., 2004) and 6–8 h in
humans, although its duration of anticonvulsant activity in humans is longer than would be
predicted by its pharmacokinetics (Perucca and Johannessen, 2003), possibly due to
sequestration of LEV in recycled synaptic vesicles where it exerts its effect through
inhibition of vesicular glutamate release (Meehan et al., 2011).
In the first experiment, acute LEV administration increased alcohol intake but did not affect
sucrose intake in a DID procedure. Most pharmacological treatments that have been
investigated suppress binge-like alcohol drinking in C57 mice (Sprow and Thiele, 2012) and
only a few, including the GABAB receptor agonist baclofen, the histamine H3 receptor
agonist immepip, and the cannabinoid agonist WIN 55–212,2 have been shown to increase
alcohol intake in similar procedures (Moore et al., 2007; Linsenbardt and Boehm, 2009;
Nuutinen et al., 2011). Both histamine H3 (Osorio-Espinoza et al., 2011) and cannabinoid
CB1 receptors (Huang et al., 2001) have been shown to act as presynaptic heteroreceptors
that inhibit glutamate release in basal ganglia, suggesting that LEV, which also inhibits
excitatory neurotransmission in limbic motor circuits (Robinson et al., 2013), may be acting
in a similar manner to increase alcohol intake under the DID access schedule. The increased
alcohol drinking after LEV treatment in C57 mice is also consistent with the finding in
humans that moderate alcohol drinkers increased their intake while receiving LEV (Mitchell
et al., 2012).
The amounts of alcohol consumed in the current every-other day DID procedure
(approximately 1.25 g/kg/h) were slightly less than those reported for other variations of the
DID procedure which are typically in the range of 1.75 g/kg/h (Rhodes et al., 2005; Sparta et
al., 2008; Holstein et al., 2011). The repeated handling and injections necessary for the
within-subjects comparison could have caused this somewhat lower level of intake, as
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alcohol intake was higher before daily handling and every-other day injections began.
Nonetheless, blood alcohol levels approximated 80 mg/dl in two hours, indicating that this
procedure produced pharmacologically relevant levels of alcohol intake.
It is possible that LEV increased alcohol intake in our DID experiments by attenuating the
suppressive effects of handling and injection stressors. LEV has been shown to reduce
anxiety-like behavior in the elevated plus maze and Vogel conflict test (Lamberty et al.,
2002; Gower et al., 2003) and other compounds with anxiolytic effects can increase alcohol
intake (Boyle et al., 1993; Sinnott et al., 2002). However, because LEV did not affect
alcohol intake in the first hour of drinking, the time closest to the injection stressor, it is
more likely that LEV affects drinking through a mechanism other than anxiety reduction.
The effect of LEV to increase alcohol drinking in the DID procedure was not immediate.
Rather, LEV appeared to have a greater effect as the mice drank more alcohol into the later
stages of the 4-h drinking session. It is unlikely that this time course is simply the result of a
slow onset of action, as LEV has been shown to have rapid effects on both seizure
thresholds in seizure-kindled rodents (Gower et al., 1992) as well as on the behavioral
effects of experimenter administered alcohol and cocaine (Robinson et al., 2013). The longer
time course we observe on DID may be related to the fact that the pharmacodynamics of
LEV may be activity dependent. LEV rapidly crosses the blood-brain barrier (Tong and
Patsalos, 2001), but its access to the intravesicular SV2A binding site is limited by the
frequency and duration of vesicular opening at presynaptic terminals of neurons activated
above basal firing levels (Yang and Rothman, 2009; Meehan et al., 2011). The fact that LEV
increased alcohol intake only after the first hour of drinking suggests that rising blood
alcohol levels could have stimulated sufficient activity in limbic motor circuits to enable
LEV to access its binding site, thereby affecting neurotransmission and changing behavior.
We have previously demonstrated that similar absolute blood alcohol concentrations during
the rising but not the falling phase potentiate electrical brain stimulation reward (BSR) in
C57BL/6J mice (Fish et al., 2010).
Enjoyment of the pharmacological effects of alcohol is hypothesized to motivate alcohol
drinking in humans (Seevers, 1968), at least initially. The levels of alcohol consumed in the
current experiments have been shown to activate the mesocorticolimbic neural circuitry that
mediates reward and reinforcement (Imperato and Di Chiara, 1986; Williams-Hemby and
Porrino, 1997), and to enhance the sensitivity of these brain reward pathways to brain
stimulation reward (Fish et al., 2010). Recent preclinical experiments have shown that LEV
can block the potentiating effects of alcohol on intracranial self-stimulation and reduce
alcohol-stimulated motor activity, suggesting that LEV may prevent alcohol from activating
these limbic motor circuits (Robinson et al., 2013). In the DID procedure, mice may
therefore have increased their alcohol consumption in order to overcome pharmacological
blockade of alcohol reward and establish the expected state of enhanced reward. This
hypothesis is supported by a subset of lower-drinking individuals in the Mitchell et al. study
(2012) who reported drinking more alcohol because they felt less intoxicated. This
possibility suggests caution for pharmacotherapy designed to block the pleasurable effects of
alcohol in moderate drinkers. Moreover, it emphasizes the need for both preclinical and
clinical studies to compare drug treatments across different patterns of alcohol drinking.
The high levels of alcohol consumption achieved during the 24-h IA schedule are consistent
with those of Hwa et al. (2011), and escalation was observed following the second week at
the 20% alcohol concentration, also replicating the findings of Melendez (2011) with every-
other day access to 15% alcohol. In contrast to its potentiating effects on DID, LEV
decreased alcohol intake in the IA mice. The lower doses (0.3, 3, and 10 mg/kg) decreased
cumulative alcohol intake in the first four hours while the higher doses (30 and 100 mg/kg)
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were without significant effects. Relative to injection with saline vehicle, none of these
doses significantly affected sucrose or concurrently measured water intake, indicating a
specific effect on alcohol drinking. Reduced alcohol intake was evident early in the 24-h
session, suggesting that neural activity within mesolimbic reward circuitry may have been
sufficient before the time of alcohol presentation for LEV to gain access to SV2A binding
sites. Support for this idea comes from a recent study finding elevated basal cell firing in the
nucleus accumbens of rats drinking alcohol on an intermittent rather than a continuous
schedule (Hopf et al., 2011).
Alcohol drinking and alcohol preference remained suppressed over the entire 24-h session,
suggesting the absence of a rebound in alcohol consumption as LEV was excreted and that
LEV did not alter overall fluid intake. Surprisingly, the effects of LEV on 24-h alcohol
drinking and alcohol preference approximated a step-function, as all LEV doses either met
or approached statistically significant differences from the saline vehicle. It should be noted
that even though alcohol drinking was suppressed, mice still consumed quantities of alcohol
(approximately 15 g/kg over the 24-h period) that are more typical of mice drinking alcohol
on a continuous schedule (Hwa et al., 2011; Melendez, 2011). These data suggest that LEV
could interfere with the neural mechanisms and adaptations engaged by the history of 24-h
intermittent alcohol access. That LEV affected DID differently than IA indicates that the
duration of alcohol access (4 vs. 24-h access) may be important to determining how LEV
affects alcohol consumption. Kindling and increased glutamatergic activity resulting from
cycles of heavy alcohol drinking and forced abstinence is an attractive hypothetical
mechanism for the effects seen following 24-h intermittent access (Ballenger and Post,
1978; Kokka et al., 1993; Ulrichsen et al., 1995; Becker et al., 1997). In this regard, LEV
may be acting like other compounds that target the glutamate system, such as acamprosate,
which are thought to reduce alcohol drinking by normalizing abnormally heightened neural
activity (Gass and Olive, 2008). Heightened excitability of brain reward circuitry above
normal basal activity after 24-h alcohol drinking (Hopf et al., 2011) may provide a substrate
upon which LEV may act to inhibit activity of these limbic motor pathways earlier and more
potently in the drinking session, resulting in decreased IA alcohol consumption. SV2A
levels have also been shown to change with kindled seizure activity and in chronic epilepsy
(van Vliet et al., 2009; Ohno et al., 2012) raising the possibility that expression of SV2A, the
pharmacological target of LEV, could also change during 24-h intermittent alcohol drinking
over several days.
A relatively low sucrose concentration (0.5%) was used in these experiments for the purpose
of eliciting comparable volumes of alcohol and sucrose intake. Although the sucrose
drinking mice consumed more fluid than did the alcohol drinking mice (1.2 ml sucrose vs.
0.83 ml alcohol), both drug-induced increases and decreases in sucrose intake could have
still been detected. Future investigations with higher sucrose concentrations, such as the
10% concentrations used in previous studies (Sparta et al., 2008; Lowery et al., 2010), could
more directly test if LEV affects preference for sweet solutions. Whether LEV may have
altered the tolerance for a bitter flavor was also not directly tested in the current
experiments. However, the findings of our IA experiment argue against tolerance of an
aversive taste, as LEV had the opposite effect, namely, to decrease alcohol intake.
Three controlled clinical trials on the efficacy of LEV to affect alcohol drinking in humans
have not found significant reductions in alcohol intake, and our present data showing an
increase in DID drinking in a preclinical model are consistent with the findings of Mitchell
et al. (2012) in heavy social drinkers. However, our present data showing decreased alcohol
drinking in the 24-h IA drinking procedure in a mouse model are not consistent with the
findings of Richter et al. (2012) in detoxified alcoholics or Fertig et al. (2012) in treatment-
seeking, alcohol-dependent outpatients. The differential effects of LEV on alcohol drinking
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in mice using the two different alcohol drinking procedures suggest that the effects of LEV
on human alcohol consumption might also be specific to individuals who engage in certain
patterns of drinking, and may not be expected to yield complete abstinence in an actively,
heavily-drinking individual. It may also help explain the discrepancy in the positive results
of clinical studies of acute alcohol detoxification, in which LEV may still have a role, and
the negative results of clinical studies on longer-term reduction in drinking or maintenance
of sobriety. Given our preclinical results it may therefore be premature to categorize LEV as
a failed therapeutic for alcoholism (Le Strat, 2012). Continued preclinical exploration of
potential drug therapies may inform clinical studies by identifying subtypes of patients with
alcohol abuse disorders in whom different pharmacotherapies may have the greatest
likelihood of success.
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Habituation to alcohol and sucrose drinking in experiment 1. Mice had access to a single
bottle containing alcohol (20% v/v, gray circles, n = 13 mice) or sucrose (0.5% w/v, white
triangles, n = 11 mice) placed into their home cages every other day. On the first two
drinking days (to the left of the dashed line) mice had 2-h access to the drinking solutions.
On subsequent drinking days, mice had 4-h access to the drinking solutions. Saline
injections (i.p.) were administered 30 min prior to the drinking session on the 14th and 15th
drinking days (gray shading). Data are expressed as mean volume (ml, top panel) or
quantity (g/kg, bottom panel) of alcohol and sucrose intake ± SEM (vertical lines).
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Levetiracetam effects on alcohol and sucrose intake in experiment 1. Data are expressed as
mean cumulative intake (g/kg) of alcohol (gray circles, n = 13 mice) and sucrose (white
triangles, n = 11 mice) across the first, second, third, and fourth 1-h time periods ± SEM
(vertical lines). V = saline vehicle. Asterisks indicate LEV doses at which alcohol
consumption is significantly different from saline vehicle (p ≤ 0.05).
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Habituation to alcohol and sucrose drinking in experiment 2. Mice had access to two bottles
placed into their home cages for 24 h on Monday, Wednesday, and Friday. One bottle
contained alcohol (gray circles, n = 11 mice) or sucrose (white triangles, n = 12 mice); the
other bottle contained tap water. Data are expressed as mean cumulative volume (ml, top
panelsA and B) or quantity (g/kg, bottom panelsC and D) of alcohol and sucrose intake ±
SEM (vertical lines). On the first three drinking days, mice had access to escalating
concentrations of alcohol (3, 6, 10% w/v) or sucrose (0.1, 0.17, 0.3 % w/v). On subsequent
drinking days, mice had access to 20% alcohol (w/v) or 0.5% sucrose (w/v). Left panels (A
and C) show cumulative intake during the first four hours of drinking. Right panels (B and
D) show cumulative intake during the entire 24 hours of drinking. Saline injections (i.p.)
were administered 30 min prior to the drinking session on the 16th, 17th, and 18th drinking
days (gray shading).
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Levetiracetam effects on alcohol and sucrose intake during the first 4 h of drinking in
experiment 2. Data are expressed as mean cumulative intake (g/kg) of alcohol (gray filled
circles, n = 11 mice) and sucrose (white triangles, n = 12 mice) across the first, second,
third, and fourth one-hour time periods ± SEM (vertical lines). V = saline vehicle. Asterisks
indicate LEV doses at which alcohol consumption is significantly different from saline
vehicle (p ≤ 0.05).
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Levetiracetam effects on total alcohol and sucrose intake (A) and preference (B) during the
entire 24 h of drinking in experiment 2. A. Data are expressed as mean cumulative intake (g/
kg) of alcohol (gray circles) and sucrose (white triangles) ± SEM (vertical lines). B. Data
are expressed as mean preference ratios for alcohol (gray circles) and sucrose (white
triangles) ± SEM (vertical lines). V = saline vehicle. Asterisks indicate LEV doses at which
consumption or preference are significantly different from saline vehicle (p ≤ 0.05).
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Levetiracetam effects on blood alcohol concentrations after 1.0 g/kg alcohol. Data are
expressed as mean blood alcohol concentrations (mg/dl) of mice treated with saline (open
circles) or 10 mg/kg levetiracetam (gray circles) ± SEM (vertical lines).
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